Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (BCRX) has announced a pause in the enrollment of new patients in its clinical trials for BCX9930 due to elevated serum creatinine levels observed in some participants. This affects the REDEEM-1, REDEEM-2, and RENEW trials, although current participants will continue their treatment. The company is investigating these safety concerns before proceeding further. BioCryst develops medicines for rare diseases and continues to progress with other drugs in its pipeline.

BioCryst Pharmaceuticals (BCRX) granted stock options and restricted stock units (RSUs) to 19 newly-hired employees on March 31, 2022. The total stock options cover 124,800 shares and RSUs cover 47,400 shares, with an exercise price of $16.26 per share, equivalent to the closing stock price on the grant date. The options and RSUs vest annually over four years, contingent on continued employment. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with BioCryst’s Inducement Equity Incentive Plan.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in upcoming healthcare conferences. The company will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. ET and at the Barclays Global Healthcare Conference in Miami Beach, Florida, on March 16, 2022, at 2:35 p.m. ET. Both presentations will be available via live audio webcast on BioCryst's website. The company focuses on developing innovative treatments for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir).

BioCryst Pharmaceuticals (BCRX) announced the grant of stock options and restricted stock units (RSUs) to 17 new employees, totaling 290,000 shares. The options have an exercise price of $16.61, aligned with the closing stock price on February 28, 2022. These grants aim to attract talent as part of Nasdaq Listing Rule 5635(c)(4). The options and RSUs will vest over four years, contingent on continued employment. BioCryst specializes in oral treatments for rare diseases and continues to advance its product pipeline including ORLADEYO and BCX9930.

BioCryst Pharmaceuticals (BCRX) announced promising long-term efficacy and safety results from the APeX-2 trial of ORLADEYO (berotralstat), aimed at treating hereditary angioedema (HAE). Data presented at the 2022 AAAAI annual meeting revealed that patients had a remarkable average of 94 percent attack-free days over 96 weeks. The study involved 121 patients, showing sustained attack rate reductions across various groups. ORLADEYO was well-tolerated, with no serious adverse events, suggesting its potential as an effective prophylactic therapy.

BioCryst Pharmaceuticals reported Q4 2021 revenues of $47.2 million, driven largely by $46.2 million from ORLADEYO, marking a significant increase from $4 million in Q4 2020. For FY 2021, total revenues reached $157.2 million, with ORLADEYO contributing $122.6 million. The company anticipates 2022 ORLADEYO revenues of no less than $250 million. With over $500 million in cash, BioCryst plans to expand its pipeline, focusing on the advancements in its Factor D programs for rare diseases.

BioCryst Pharmaceuticals (BCRX) has enrolled its first patient in the RENEW study, aimed at assessing the oral Factor D inhibitor, BCX9930, in renal diseases such as C3 glomerulopathy, IgAN, and PMN. This multicenter trial will involve about 42 patients receiving BCX9930 over 24 weeks, with the primary endpoint being the change in urine protein-to-creatinine ratio. The company is also advancing its clinical efforts with BCX9930 in ongoing REDEEM trials for PNH, seeking to establish regulatory approvals over the next two years.

BioCryst Pharmaceuticals, Inc. (BCRX) plans to release its fourth quarter and full year 2021 financial results on February 23, 2022. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call via telephone or online, with a replay available afterward. BioCryst specializes in discovering novel oral medicines for rare diseases, with products like ORLADEYO and ongoing development programs targeting complement-mediated diseases and viral infections.

BioCryst Pharmaceuticals has appointed Machelle Sanders, North Carolina Secretary of Commerce and a veteran in pharmaceutical operations, to its board of directors. With over 30 years of experience, including leadership roles at Biogen, Sanders brings extensive expertise in scaling operations while maintaining quality control. Her appointment comes as BioCryst builds on the success of ORLADEYO, its recently launched oral treatment for rare diseases. Sanders emphasized the potential for growth through effective commercialization and innovation in R&D.